Simon Kariuki

List of Publications by Year in Descending Order

27 papers	3,003 citations	14 h-index	27 g-index
27 ext. papers	3,612 ext. citations	17.6 avg, IF	3.37 L-index

#	Paper	IF	Citations
27	Intermittent screening and treatment with artemisinin-combination therapy versus intermittent preventive treatment with sulphadoxine-pyrimethamine for malaria in pregnancy: a systematic review and individual participant data meta-analysis of randomised clinical trials. *EClinicalMedicine*,	11.3	1
26	Healthcare provider and pregnant women's perspectives on the implementation of intermittent screening and treatment with dihydroartemisinin-piperaquine for malaria in pregnancy in western Kenya: a qualitative study. *Malaria Journal*, **2021**, 20, 291	3.6	1
25	Adoption of evidence-based global policies at the national level: intermittent preventive treatment for malaria in pregnancy and first trimester treatment in Kenya, Malawi, Mali and The Gambia. *Health Policy and Planning*, **2021**, 35, 1364-1375	3.4	0
24	Piperaquine Pharmacokinetics during Intermittent Preventive Treatment for Malaria in Pregnancy. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	2
23	Cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine for malaria during pregnancy: an analysis using efficacy results from Uganda and Kenya, and pooled data. *The Lancet Global Health*, **2020**, 8, e1512-e1523	13.6	0
22	Counter-Selection of Antimalarial Resistance Polymorphisms by Intermittent Preventive Treatment in Pregnancy. *Journal of Infectious Diseases*, **2020**, 221, 293-303	7	3
21	Malaria Chemoprevention in the Postdischarge Management of Severe Anemia. *New England Journal of Medicine*, **2020**, 383, 2242-2254	59.2	9
20	Intermittent screening and treatment with dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy: implementation feasibility in a routine healthcare system setting in western Kenya. *Malaria Journal*, **2020**, 19, 433	3.6	2
19	Modelling the incremental benefit of introducing malaria screening strategies to antenatal care in Africa. *Nature Communications*, **2020**, 11, 3799	17.4	9
18	Assessment of molecular markers of anti-malarial drug resistance among children participating in a therapeutic efficacy study in western Kenya. *Malaria Journal*, **2020**, 19, 291	3.6	4
17	Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy. *Nature Communications*, **2019**, 10, 2174	17.4	63
16	Knowledge and Adherence to the National Guidelines for Malaria Diagnosis in Pregnancy among Health-Care Providers and Drug-Outlet Dispensers in Rural Western Kenya. *American Journal of Tropical Medicine and Hygiene*, **2018**, 98, 1367-1373	3.2	2
15	Malaria chemoprevention with monthly dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: study protocol for a multi-centre, two-arm, randomised, placebo-controlled, superiority trial. *Trials*, **2018**,	2.8	8
14	Malaria, malnutrition, and birthweight: A meta-analysis using individual participant data. *PLoS Medicine*, **2017**, 14, e1002373	11.6	25
13	Estimates of burden and consequences of infants born small for gestational age in low and middle income countries with INTERGROWTH-21 standard: analysis of CHERG datasets. *BMJ, The*, **2017**, 358, j3677	5.9	145
12	User and Provider Acceptability of Intermittent Screening and Treatment and Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine to Prevent Malaria in Pregnancy in Western Kenya. *PLoS ONE*, **2016**, 11, e0150259	3.7	19
11	Maternal Malaria and Malnutrition (M3) initiative, a pooled birth cohort of 13 pregnancy studies in Africa and the Western Pacific. *BMJ Open*, **2016**, 6, e012697	3	4

List of Publications

10	Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. *Lancet, The*, **2015**, 386, 2507-19	40	127
9	In Vitro and Molecular Surveillance for Antimalarial Drug Resistance in Plasmodium falciparum Parasites in Western Kenya Reveals Sustained Artemisinin Sensitivity and Increased Chloroquine Sensitivity. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 7540-7	5.9	22
8	Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. *New England Journal of Medicine*, **2015**, 373, 2025-2037	59.2	225
7	Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. *American Journal of Tropical Medicine and Hygiene*, **2014**, 91, 833-843	3.2	167
6	National and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010. *The Lancet Global Health*, **2013**, 1, e26-36	13.6	404
5	A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. *New England Journal of Medicine*, **2012**, 367, 2284-95	59.2	514
4	First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. *New England Journal of Medicine*, **2011**, 365, 1863-75	59.2	626
3	Polymorphisms in genes of interleukin 12 and its receptors and their association with protection against severe malarial anaemia in children in western Kenya. *Malaria Journal*, **2010**, 9, 87	3.6	21
2	Protective effects of the sickle cell gene against malaria morbidity and mortality. *Lancet, The*, **2002**, 359, 1311-2	40	442
1	A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. *Lancet, The*, **2002**, 360, 1468-75	40	158